Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, is approved by the U.S. Food and Drug Administration (USFD...
Product Name : Sapropterin Dihydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2021
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating the commitment to bring affordable generic medicines to market for patients. Dr. Reddy’s Sapropterin Dihydrochloride Tablets, 100 mg are available in bottl...
Product Name : Sapropterin Dihydrochloride-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2020
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Therapeutics Reports Positive Results from RLF-OD032 Study For Phenylketonuria
Details : RLF-OD032 (sapropterin dihydrochloride) is a PAH agonist small molecule drug candidate which is being evaluated for the treatment of phenylketonuria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2024
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Completes Phase in RLF-OD032 Study; Topline Results Expected October 2024
Details : RLF-OD032, an innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, is designed to lower blood phenylalanine in adult and pediatric PKU patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2024
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC
Details : Sapropterin Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 02, 2024
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : BioMarin Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tetrahydrobiopterin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Intermittent Claudication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 16, 2021
Lead Product(s) : Sapropterin Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : BioMarin Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable